Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Total Non-Current Liabilities (2020 - 2025)

Historic Total Non-Current Liabilities for Arcutis Biotherapeutics (ARQT) over the last 6 years, with Q3 2025 value amounting to $212.5 million.

  • Arcutis Biotherapeutics' Total Non-Current Liabilities fell 2417.08% to $212.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $212.5 million, marking a year-over-year decrease of 2417.08%. This contributed to the annual value of $190.8 million for FY2024, which is 2424.91% down from last year.
  • As of Q3 2025, Arcutis Biotherapeutics' Total Non-Current Liabilities stood at $212.5 million, which was down 2417.08% from $213.1 million recorded in Q2 2025.
  • Over the past 5 years, Arcutis Biotherapeutics' Total Non-Current Liabilities peaked at $280.3 million during Q3 2024, and registered a low of $18.4 million during Q2 2021.
  • For the 5-year period, Arcutis Biotherapeutics' Total Non-Current Liabilities averaged around $170.5 million, with its median value being $206.8 million (2025).
  • As far as peak fluctuations go, Arcutis Biotherapeutics' Total Non-Current Liabilities soared by 89299.47% in 2022, and later tumbled by 2424.91% in 2024.
  • Over the past 5 years, Arcutis Biotherapeutics' Total Non-Current Liabilities (Quarter) stood at $110.4 million in 2021, then soared by 117.01% to $239.7 million in 2022, then grew by 5.07% to $251.8 million in 2023, then dropped by 24.25% to $190.8 million in 2024, then grew by 11.41% to $212.5 million in 2025.
  • Its Total Non-Current Liabilities stands at $212.5 million for Q3 2025, versus $213.1 million for Q2 2025 and $201.1 million for Q1 2025.